uniQure tumbles after updated Huntington's disease gene therapy data
BUZZ-uniQure tumbles after updated Huntington's disease gene therapy data Updates
** US-listed shares of gene therapy developer uniQure UQ1.F, QURE.O fall 38% to $24.25
** Stock hits lowest level in over four months
** Co says its experimental gene therapy for Huntington's disease, an inherited brain disorder, continued to slow disease progression in an early- to mid-stage study
** Updated 36-month data showed 80% slowing of disease progression on cUHDRS, a measure of Huntington's disease progression, and 67% on Total Functional Capacity, the main measure in its confirmatory study
** At 48 months, cUHDRS, the primary endpoint, showed 44% slowing but missed statistical significance; Total Functional Capacity showed 61% slowing
** FDA previously accepted 36-month data as the basis for the company's accelerated approval application
** Including sessions move, stock up ~1 YTD
(Reporting by Sahil Pandey in Bengaluru)
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal